Dopaminergic alterations in patients with Alzheimer’s disease
Objective: The objective of this study was to conduct a meta-analysis to determine the pooled mean difference (MD) in dopaminergic measures between Alzheimer’s disease and…In Silico Electrophysiology and System Pharmacology Reveal Coupling Between Dopamine Receptors and Ca2+ Channels in Subthalamic Neuronal Cells towards Parkinson’s Disease
Objective: Recent experimental evidence suggests a potential interaction between dopamine D2 receptors (D2R) and N-type Ca2+ channels, impacting the firing patterns of Subthalamic neuronal (STN)…Dopamine Receptor Gene Polymorphism in L-Dopa Induced Dyskinesia- A Study from Eastern India
Objective: We intended to find the frequency of Single Nucleotide Polymorphism (SNP) rs6280 in DRD3 gene in PD patients with and without Levodopa Induced Dyskinesia…Identification of xylopropamine as a potential dopamine D2 receptor agonist through computational drug discovery pipeline
Objective: This study aims to identify novel dopamine D2 receptor agonists through the computational drug discovery pipeline. Background: Parkinson's disease (PD) is a neurodegenerative disorder…Quantification of Striatal and Extrastriatal Dopamine Transporters with [18F]PR04.MZ and [18F] PI- 2620 PET in Patients with Progressive Supranuclear Palsy.
Objective: We aim to evaluate the differences in striatal subregional dopamine transporter loss between Parkinson disease (PD) and progressive supranuclear palsy (PSP) of any stage…Long-term safety and durability of effect of ecopipam in pediatric patients with Tourette Syndrome: Results of a 12-month open-label extension (OLE) study
Objective: Assess the safety and durability of effect of long-term treatment with ecopipam in pediatric patients with Tourette syndrome (TS). Background: TS is a childhood-onset…Preclinical characterization of UCB0022, an oral, brain penetrant, selective, clinical-stage positive allosteric modulator of the dopamine 1 receptor (D1 PAM)
Objective: To characterize the in vitro and in vivo pharmacologic profile of UCB0022 Background: Parkinson’s disease (PD) is a progressive neurodegenerative disease with reductions in…PP1α negatively regulates D2 receptor mediated cadmium induced motor dysfunctions: protective potential of Quercetin.
Objective: The present study has been focused to identify the molecular targets that involved in Cadmium-induced motor dysfunctions. At the same time, we also focused…The study of genetic factors in motor levodopa-induced complications development in Russian patients with Parkinson’s disease
Objective: This study is aimed to explore the relationship between the single nucleotide polymorphisms (SNPs) in dopamine metabolism genes and development of motor side effects…Using a Dopamine Genetic Risk Score to Predict Impulse Control Behaviours for Parkinson’s Disease Patients
Objective: The current study aimed to utilise a dopamine genetic risk score and objective laboratory-based behavioural measures of impulse control to identify Parkinson’s patients most…
- 1
- 2
- 3
- …
- 5
- Next Page »